Sonia Maria Freitas de Morais

Profissional com extensa experiencia em Pesquisa e Desevolvimento na Industria Farmaceutica. Atualmente trabalha como Director of Drug Metabolism and Pharmacokinetics na Global Pharmaceutical Research and Development da AbbVie Inc. (Ex-Abbott Pharmaceuticals) em Chicago, EUA. Possui mestrado em Ciências Farmacêuticas pela Universidade de São Paulo (1984) em programa sandwiche com a Universidade de Bath da Inglaterra; e doutorado em PhD em Farmacia pela University of Toronto (1990). Fez pos-doutorado no National Institutes of Environmental Health Sciences (part of NIH) na area de farmacogenomica. Descobriu o polimorfismo genetico do citocromo CYP2C19, o qual foi patenteado pelo NIH. Alem da AbbVie/Abbott, tem experiencia de P&D de 4 anos na Boehringer Ingelheim, e 10 anos na Pfizer Global Research and Development, nos EUA. Possui grau de Executive MBA pela Rensselaer Polytechnic University, de Hartford, Connecticut em 2003. Tem experiencia em assuntos regulatorios preclinicos junto ao FDA e EMA, propriedade intelectual, freedom-to-operate, e business development, com parcerias entre universidades, instituicoes de pesquisa e companias farmaceuticas.

Informações coletadas do Lattes em 20/10/2025

Acadêmico

Formação acadêmica

Doutorado em PhD em Farmacia

1985 - 1990

University of Toronto
Título: UDP-Glucuronyl Transferase Deficiency as a Biochemical Determinant of Chemical Toxicity
Orientador: Peter G Wells
Bolsista do(a): Conselho Nacional de Desenvolvimento Científico e Tecnológico.

Mestrado em Ciências Farmacêuticas

1981 - 1984

Universidade de São Paulo
Orientador: Eugenio Aquarone
Bolsista do(a): Enciclopedia Britanica.

Mestrado profissional em Executive MBA

2002 - 2003

Rensselaer Polytechnic University
Orientador: Nao se aplica
Grande área: Ciências Sociais Aplicadas / Área: Administração / Subárea: Administração de Empresas. Grande Área: Ciências Sociais Aplicadas / Área: Economia / Subárea: Economia Internacional. Grande Área: Ciências Sociais Aplicadas / Área: Economia / Subárea: Métodos Quantitativos em Economia.

Pós-doutorado

1992 - 1995

Pós-Doutorado. , National Institute of Environmental Health Sciences. , Bolsista do(a): National Institute of Environmental Health Sciences. , Grande área: Ciências Biológicas / Área: Farmacologia / Subárea: Farmacologia Bioquímica e Molecular. , Grande Área: Ciências Biológicas / Área: Genética / Subárea: Genética Humana e Médica.

1990 - 1991

Pós-Doutorado. , University of Toronto, UTORONTO, Canadá. , Grande área: Ciências Biológicas / Área: Farmacologia / Subárea: Toxicologia.

Idiomas

Inglês

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Espanhol

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Italiano

Compreende Pouco, Fala Pouco, Lê Pouco, Escreve Pouco.

Francês

Compreende Razoavelmente, Fala Razoavelmente, Lê Razoavelmente, Escreve Pouco.

Alemão

Compreende Bem, Fala Razoavelmente, Lê Razoavelmente, Escreve Pouco.

Participação em eventos

American Chemical Society (ACS) National Meeting and Exposition. Automated high-throughput assay for microsomal binding with ultra fast liquid chromatography-tandem mass spectrometry. 2012. (Congresso).

17th North American Regional ISSX Meeting. Evaluation of ADMET properties predictions using the advanced in silico modeling tool ADMET predictor. 2011. (Congresso).

11th North American ISSX Meeting. Fluorescent transporter inhibition assays. 2002. (Congresso).

6th International ISSX Meeting. Assessment of induction of drug metabolizing enzymes in humans with Invader technology. 2001. (Congresso).

8th North American ISSX Meeting. Niverapine hydroxylation, an in vitro probe for the simultaneous determination of CYP3A and CYP2B6 activity in human liver microsomes. 1997. (Congresso).

7th North American ISSX Meeting. A novel genetic defect of human CYP2C19 responsible for the poor metabolizer of Smephenytoin: mutation of the initiation codon. 1996. (Congresso).

34th Annual meeting of the Society of Toxicology. Evaluation of the role of CYP2C19 genotype and bladder cancer. 1995. (Congresso).

6th North American ISSX Meeting. Identification of a new genetic defect responsible for the polymorphism of Smephenytoin metabolism in oriental populations. 1994. (Congresso).

XIIth International Congress of Pharmacology. Molecular structure and polymorphism in the human CYP2C19 gene. 1994. (Congresso).

10th International Symposium on Microsomes and Drus Oxidations. Unravelling the molecular mechanism of mephenytoin polymorphism. 1994. (Congresso).

ASBMB\ISSX satellite meeting. Alterations in human CYP2C19, the major s-mephenytoin 4´hydroxylase, in poor metabolizers of S-mephenytoin. 1994. (Congresso).

Federation of American Societies for Experimental Biology. Gene structure and regulatory upstream regions of two human cytochromes P4502C (2C9 and 2C18) associated with S-mephenytoin hydroxylation. 1993. (Congresso).

Society of Toxicology. Correlation of the P4502C subfamily substrate selectivities with primary structures. 1993. (Congresso).

Drug Metabolism Meeting of the Gordon Research Conferences. Substrate selectivity of the human P4502C subfamily using warfarin as a probe. 1992. (Congresso).

Fourth American ISSX Meeting. Correlation of the P4502C subfamily substrate selectivities with primary structures - warfarin as a probe. 1992. (Congresso).

Proc. Can. Fed. Biol. Soc.. Photoaffinitty labelling of the Ah receptor with | H|3-methylcholanthrene. 1991. (Congresso).

Pharmacologist. | H|3-Methylcholanthrene as a photoaffinitty label for the Ah receptor. 1991. (Congresso).

Federation of American Societies for Experimental Biology. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert`s disease. 1989. (Congresso).

Pharmacologist. In vitro studies on the mechanism of acetaminophen toxicity in Gunn rats. 1988. (Congresso).

Hepatology. Comparison of acetaminophen biotransformation in three strains of rat with glucuronyl transferase deficiency. 1988. (Congresso).

Acta Physiol. Pharmacol. (Latino Americana). Glucuronyl transferase phenotype as a genetic determinant of acetaminophen hepatotoxicity. 1987. (Congresso).

Fed. Proc.. Enhanced acetaminophen toxicity in Gunn rats. 1987. (Congresso).

Produções bibliográficas

LIU, HONG ; DENG, XIAOQING ; LIU, JINRONG ; LIU, NING ; STUART, PATRICIA ; XU, HONGYU ; GUAN, ZHIWEN ; MARSH, KENNAN C. ; de Morais, Sonia M. . Species-dependent metabolism of a novel selective α7 neuronal acetylcholine receptor agonist ABT-107. Xenobiotica (London. Print) , v. 43, p. 803-816, 2013.
CHIOU, WILLIAM J. ; de Morais, Sonia M. ; KIKUCHI, RYOTA ; VOORMAN, RICHARD L. ; LI, XIAOFENG ; BOW, DANIEL A. J. . OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica (London. Print) , v. TBD, p. 1-7, 2013.
KIKUCHI, R. ; de Morais, S. M. ; KALVASS, J. C. . In Vitro P-gp Efflux Ratio Can Predict The In Vivo Brain Penetration Regardless of BDDCS Class. Drug Metabolism and Disposition , v. 41, p. ahead of print, 2013.
Li, X. ; Delzer, J. ; Voorman, R. ; de Morais, S. M. ; Lao, Y. . Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase. Drug Metabolism and Disposition , v. 39, p. 1161-1169, 2011.
Warren, Mark S. ; Zerangue, Noa ; Woodford, Katie ; Roberts, Lori M. ; Tate, Emily H. ; Feng, Bo ; Li, Cheryl ; Feuerstein, Thomas J. ; Gibbs, John ; Smith, Bill ; de Morais, S. M. F. . Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacological Research , v. 59, p. 404-413, 2009.
Chen, C. ; Stock, J. L. ; Liu, X. ; Shi, J. ; Van Deusen, J. W. ; DiMattia, D. A. ; Dullea, R. G. ; de Morais, S. M. . Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds. Drug Metabolism and Disposition , v. 36, p. 1840-1845, 2008.
Feng, B. ; Mills, J. B. ; Davidson, R. E. ; Mireles, R. J. ; Janiszewski, J. S. ; Troutman, M. D. ; DE MORAIS, S. M. F. . In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System. Drug Metabolism and Disposition , v. 36, p. 268-275, 2007.
Smith, D. A. ; Dickins, M. ; Fahmi, O. A. ; Iwasaki, K. ; Lee, C. ; Obach, R. S. ; Padbury, G. ; de Morais, S. M. ; Ripp, S. L. ; Stevens, J. ; Voorman, R. ; Youdim, K. . The Time to Move Cytochrome P450 Induction into Mainstream Pharmacology Is Long Overdue. Drug Metabolism and Disposition , v. 35, p. 697-698, 2007.
Feng, B ; Obach, RS ; Burstein, AH ; Clark, DJ ; de Morais, SM ; Faessel, HM . Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro In Vivo Study. Clinical Pharmacology and Therapeutics , v. 83, p. 567-576, 2007.
Sharon L. Ripp ; Jessica B. Mills ; Odette A. Fahmi ; Kristen A. Trevena ; Jennifer L. Liras ; Tristan S. Maurer ; de Morais, S. M. . Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction. Drug Metabolism and Disposition , v. 34, p. 1742-1748, 2006.
Xiao, Yongling ; Davidson, Ralph ; Smith, Arthur ; Pereira, Dennis ; Zhao, Sabrina ; Soglia, John ; Gebhard, David ; de Morais, Sonia ; Duignan, David B. . A 96-Well Efflux Assay To Identify ABCG2 Substrates Using a Stably Transfected MDCK II Cell Line. Molecular Pharmaceutics (Print) , v. 3, p. 45-54, 2006.
SAHI, J ; SINZ, M ; CAMPBELL, S ; MIRELES, R ; ZHENG, X ; ROSE, K ; RAEISSI, S ; HASHIM, M ; YE, Y ; DEMORAIS, S . Metabolism and transporter-mediated drugâ . Chemico-Biological Interactions (Print) , v. 159, p. 156-168, 2006.
CAMPBELL, S ; DEMORAIS, S ; XU, J . Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chemico-Biological Interactions , v. 150, p. 179-187, 2004.
Mills, J. B. ; Rose, Kelly A. ; Sahi, Jasminder ; de Morais, S. M. . Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line. Journal of Pharmacology and Experimental Therapeutics , v. 309, p. 303-309, 2004.
LIN, J. ; Sahakian, D.C. ; de Morais, S.M. ; Xu, J.J. ; Polzer, R.J. ; Winter, S.M. . The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery. Current Topics in Medicinal Chemistry (Print) , v. 3, p. 1125-1154, 2003.
Ferguson, R.J. ; MORAIS, S. M. F. ; Benhamou, S. ; Bouchardy, C. ; Blaisdell, J. ; Ibeanu, G. ; Wilkinson, G.R. ; Sarich, T.C. ; Wright, J.W. ; Dayer, P. ; Goldstein, J.A. . A new defect in human CYP2C19: mutation of the initiation codon is responsible for the poor metabolism of S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics , v. 284, p. 356-361, 1998.
Goldstein, Joyce A. ; Ishizaki, Takashi ; Chiba, Kan ; de Morais, Sonia M.F. ; Bell, Douglas ; Krahn, Peter M. ; Price Evans, David A. . Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics (London) , v. 7, p. 59-64, 1997.
Edeki, Timi I. ; Goldstein, Joyce A. ; de Morais, Sonia M.F. ; Hajiloo, Leila ; Butler, Marcela ; Chapdelaine, Perry ; Wilkinson, Grant R. . Genetic polymorphism of S-mephenytoin 4??-hydroxylation in African-Americans. Pharmacogenetics (London) , v. 6, p. 357-360, 1996.
de Morais, Sonia M.F. ; Goldstein, Joyce A. ; Xie, Hong-Guang ; Huang, Song-Ling ; Lu, Yi-Qing ; Xia, Hui ; Xiao, Zhou-Sheng ; Ile, Nan ; Zhou, Hong-Hao . Genetic analysis of the S-mephenytoin polymorphism in a chinese population*. Clinical Pharmacology and Therapeutics , v. 58, p. 404-411, 1995.
Brosen, Kim ; de Morais, Sonia M. F. ; Meyer, Urs A. ; Goldstein, Joyce A. . A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics (London) , v. 5, p. 312-317, 1995.
de Morais, S. M. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; Goldstein, J.A. . Identification of a new genetic defect responsible for the polymorphism in S-mephenytoin metabolism in Japanese. Molecular Pharmacology (Print) , v. 46, p. 594-598, 1994.
de Morais, S. M. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; Goldstein, J.A. . The major genetic defect responsible for the polymorphism in S-mephenytoin metabolism in humans. The Journal of Biological Chemistry (Print) , v. 269, p. 15419-15422, 1994.
de Morais, S. M. ; Giannone, J.V. ; Okey, A.B. . Photoaffinitty labelling of the Ah receptor with [3H]3-methylcholanthrene and formation of a 165 kDa complex between the ligand-binding subunit and a novel cytosolic protein. The Journal of Biological Chemistry , v. 269, p. 12129-12136, 1994.
Goldstein, Joyce A. ; de Morais, Sonia M. F. . Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (London) , v. 4, p. 285-300, 1994.
Demorais, S.M.F. ; Schweikl, H. ; Blaisdell, J. ; Goldstein, J.A. . Gene Structure and Upstream Regulatory Regions of Human CYP2C9 and CYP2C18. Biochemical and Biophysical Research Communications (Print) , v. 194, p. 194-201, 1993.
Kaminsky, L.S. ; de Morais, S. M. ; Faletto, M.B. ; Dunbar, D. ; Goldstein, J.A. . Correlation of human P4502C substrate specificities with primary structures - warfarin as a probe. Molecular Pharmacology (Print) , v. 43, p. 234-239, 1993.
de Morais, Sonia M.F. ; Chow, Susanna Y.M. ; Wells, Peter G. . Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Toxicology and Applied Pharmacology , v. 117, p. 81-87, 1992.
de Morais, S. M. ; Uetrecht, J.P. ; Wells, P.G. . Decreased glucuronidation and enhanced bioactivation of acetaminophen in Gilbert's disease. Gastroenterology (New York) , v. 102, p. 577-586, 1992.
de Morais, Sonia M. F. ; Wells, Peter G. . Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology (Baltimore, Md.) , v. 10, p. 163-167, 1989.
de Morais, S. M. ; Wells, P.G. . Deficiency in bilirubin UDP-glucuronyl transferase as a genetic determinant of acetaminophen toxicity. Journal of Pharmacology and Experimental Therapeutics , v. 247, p. 323-331, 1988.
de Morais, S. M. ; Aquarone, E. ; Rose, A.H. ; Beavan, M.J. . Efeito do etanol na atividade fermentativa de Saccharomyces cerevisiae. Revista de Microbiologia , v. 17, p. 371-375, 1986.
Cartwright, C.P. ; Yuroszek, J.R. ; Beavan, M.J. ; Ruby, F.M.S. ; de Morais, S. M. ; Rose, A.H. . Ethanol Dissipates the Proton-motive Force across the Plasma Membrane of Saccharomyces cerevisiae. Microbiology (Reading. Print) , v. 132, p. 369-377, 1986.
DE MORAIS, S. M. F. ; Schweikl, H. ; Blaisdell, J. ; Goldstein, J.A. . Gene structure and regulatory upstream regions of two human cytochromes P4502C (2C9 and 2C18) associated with S-mephenytoin hydroxylation. In: Federation of American Societies for Experimental Biology, 1993. The FASEB Journal, 1993. v. 7. p. A1167.
Ibeanu, G. ; Schweikl, H. ; DE MORAIS, S. M. F. ; Goldstein, J.A. . Promotor activity of the upstream regulatory regions of the human 2C9 and 2C18 genes in HepG2 cells. In: Federation of American Societies for Experimental Biology, 1993. The FASEB Journal, 1993. v. 7. p. A1167.
DE MORAIS, S. M. F. ; Okey, A.B. . Photoaffinitty labelling of the Ah receptor with | H|3-methylcholanthrene. In: Proc. Can. Fed. Biol. Soc., 1991. Proc. Can. Fed. Biol. Soc., 1991. v. 34. p. 112.
DE MORAIS, S. M. F. ; Okey, A.B. . | H|3-Methylcholanthrene as a photoaffinitty label for the Ah receptor. In: Pharmacologist, 1991. Pharmacologist, 1991. v. 33. p. 164.
DE MORAIS, S. M. F. ; Uetrecht, J.P. ; Wells, P.G. . Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert`s disease. In: Federation of American Societies for Experimental Biology, 1989. The FASEB Journal, 1989. v. 3. p. A739.
Wells, P.G. ; Obilo, F.C. ; DE MORAIS, S. M. F. . Benzo(a)pyrene embryopathy in rats genetically deficient in bilirubin UDP-glucuronyl transferase (GT). In: Federation of American Societies for Experimental Biology, 1989. The FASEB Journal, 1989. v. 3. p. A1025.
Lee, V.M.W. ; DE MORAIS, S. M. F. ; Wells, P.G. . Effect of exogenous bilirubin on drug metabolism and acetaminophen (APAP) toxicity in CD1-mice. In: Federation of American Societies for Experimental Biology, 1989. The FASEB Journal, 1989. v. 3. p. A471.
DE MORAIS, S. M. F. ; Hu, Z. ; Nagai, M.K. ; Wells, P.G. . In vitro studies on the mechanism of acetaminophen toxicity in Gunn rats. In: Pharmacologist, 1988. Pharmacologist, 1988. v. 30. p. A100.
Chow, S.Y.M. ; DE MORAIS, S. M. F. ; Wells, P.G. . Biotransformation and toxicity of acetaminophen in congenic RHA rats with bilirubin glucuronyl transferase deficiency. In: Pharmacologist, 1988. Pharmacologist, 1988. v. 30. p. A75.
DE MORAIS, S. M. F. ; Wells, P.G. . Comparison of acetaminophen biotransformation in three strains of rat with glucuronyl transferase deficiency. In: Hepatology, 1988. Hepatology, 1988. v. 8. p. 1383.
DE MORAIS, S. M. F. ; Wells, P.G. . Glucuronyl transferase phenotype as a genetic determinant of acetaminophen hepatotoxicity. In: Acta Physiol. Pharmacol. (Latino Americana), 1987. Acta Physiol. Pharmacol. (Latino Americana), 1987. v. 37. p. 23.
DE MORAIS, S. M. F. ; Wells, P.G. . Enhanced acetaminophen toxicity in Gunn rats. In: Fed. Proc., 1987. Fed. Proc., 1987. v. 46. p. 1140.
DE MORAIS, S. M. F. ; Wells, P.G. . Enhanced acetaminophen toxicity in rats with glucuronyl transferase deficiency. In: Hepatology, 1987. Hepatology, 1987. v. 7. p. 1046.
Lau, Y.Y. ; Doktor, S. ; DE MORAIS, S. M. F. . Automated high-throughput assay for microsomal binding with ultra fast liquid chromatography-tandem mass spectrometry. 2012. (Apresentação de Trabalho/Congresso).
Li, X. ; Deshmukh, R. ; Shebley, M. ; DE MORAIS, S. M. F. . Evaluation of ADMET properties predictions using the advanced in silico modeling tool ADMET predictor. 2011. (Apresentação de Trabalho/Congresso).
Mireles, R. J. ; Kajiji, S.M. ; DE MORAIS, S. M. F. ; Xu, J.J. . Fluorescent transporter inhibition assays. 2002. (Apresentação de Trabalho/Congresso).
Campbell, S.D. ; DE MORAIS, S. M. F. . Characterization of human livers specific OATPs: Inhibition of transport and effects or serum protein binding. 2002. (Apresentação de Trabalho/Congresso).
Mills, J. B. ; Faris, R. ; Liu, Jin ; Cascio, S. ; DE MORAIS, S. M. F. . An HTS assay for induction of enzymes and transporters using a human hepatocytes clonal line and RNA detection. 2002. (Apresentação de Trabalho/Congresso).
Mills, J. B. ; ROSE, K ; SAHI, J ; DE MORAIS, S. M. F. . Assessment of induction of drug metabolizing enzymes in humans with Invader technology. 2001. (Apresentação de Trabalho/Congresso).
Erickson, A.D. ; Riska, P.S. ; Hattox, S.E. ; Walter, B.A. ; Fahmi, O. A. ; DE MORAIS, S. M. F. ; Keirns, J.J. . Niverapine hydroxylation, an in vitro probe for the simultaneous determination of CYP3A and CYP2B6 activity in human liver microsomes. 1997. (Apresentação de Trabalho/Congresso).
Ferguson, R.J. ; DE MORAIS, S. M. F. ; Benhamour, S. ; Bouchardy, C. ; Blaisdell, J. ; Wilkinson, G.R. ; Linko, P. ; Dayer, P. ; Goldstein, J.A. . A novel genetic defect of human CYP2C19 responsible for the poor metabolizer of Smephenytoin: mutation of the initiation codon. 1996. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Taylor, J.A. ; Mohler, J.L. ; Paulson, D. ; Robertson, C.N. ; Goldstein, J.A. . Evaluation of the role of CYP2C19 genotype and bladder cancer. 1995. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; Goldstein, J.A. . Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in oriental populations. 1994. (Apresentação de Trabalho/Congresso).
Goldstein, J.A. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; DE MORAIS, S. M. F. . Use of molecular biology techniques to identify genetic defects responsible for the S-mephenytoin 4´-hydroxylase polymorphism in humans. 1994. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Bell, D. ; Goldstein, J.A. . Incidence of CYP2C19 mutants in American-European, African-American and Chinese-Taiwanese individuals. 1994. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Meyer, U.A. ; Linko, P. ; Goldstein, J.A. . CYP2C19 RNA level correlates with S-mephenytoin 4´hydroxylase activity in human liver. 1994. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Goldstein, J.A. ; Hajiloo, L. ; Edeki, T.I. . Frequency of CYP2C19m1 and CYP2C19m2 mutations responsible for the S-mmephenytoins phenotype in an american black population. 1994. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; Goldstein, J.A. . Molecular structure and polymorphism in the human CYP2C19 gene. 1994. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Wilkinson, G.R. ; Blaisdell, J. ; Nakamura, K. ; Meyer, U.A. ; Goldstein, J.A. . Unravelling the molecular mechanism of mephenytoin polymorphism. 1994. (Apresentação de Trabalho/Congresso).
Ibeanu, G. ; DE MORAIS, S. M. F. ; Goldstein, J.A. . Analysis of the promotor activity of human CYP2C9 and CYP2C18 in HepG2 cells. 1994. (Apresentação de Trabalho/Congresso).
Goldstein, J.A. ; Guanayem, B.I. ; Faletto, M.B. ; Lasker, J. ; Sullivan, T. ; ROMKES-SPARKS, M. ; Raucy, G. ; Wilkinson, G.R. ; Meyer, U.A. ; DE MORAIS, S. M. F. . Alterations in human CYP2C19, the major S-mephenytoin 4´hydroxylase, in poor metabolizers of S-mephenytoin. 1994. (Apresentação de Trabalho/Congresso).
Kaminsky, L.S. ; DE MORAIS, S. M. F. ; Faletto, M.B. ; Dunbar, D. ; Goldstein, J.A. . Correlation of the P4502C subfamily substrate selectivities with primary structures. 1993. (Apresentação de Trabalho/Congresso).
DE MORAIS, S. M. F. ; Goldstein, J.A. ; Faletto, M.B. ; Dunbar, D. ; Kaminsky, L.S. . Substrate selectivity of the human P4502C subfamily using warfarin as a probe. 1992. (Apresentação de Trabalho/Congresso).
Kaminsky, L.S. ; DE MORAIS, S. M. F. ; Faletto, M.B. ; Dunbar, D. ; Goldstein, J.A. . Correlation of the P4502C subfamily substrate selectivities with primary structures - warfarin as a probe. 1992. (Apresentação de Trabalho/Congresso).
Goldstein, Joyce A. ; de Morais, S. M. F. . Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of S-mephenytoin metabolism 1999 (Patente).
Goldstein, Joyce A. ; ROMKES-SPARKS, M. ; de Morais, S. M. F. . Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of S-mephenytoin metabolism. 1995 (Patente).

Histórico profissional

Endereço profissional

AbbVie, Research and Development. , 1 N Waukegan Road R46V AP9-1, Abbott Park, 600646118 - North Chicago, - Estados Unidos, Telefone: (847) 9372361

Experiência profissional

2013 - Atual

AbbVie

Vínculo: Celetista, Enquadramento Funcional: Director of DMPK department, Carga horária: 40, Regime: Dedicação exclusiva.

Outras informações:
A empresa AbbVie foi formada pela desvinculacao da divisao farmaceutica da companhia Abbott Laboratories em 1 de Janeiro de 2013.

2008 - 2012

Abbott Laboratories

Vínculo: Diretora de Departamento, Enquadramento Funcional: Diretora, Carga horária: 40, Regime: Dedicação exclusiva.

Outras informações:
Responsavel por pesquisas de novos medicamentos, incluindo-se a parte cientifica como regulatoria e estrategica. Supervionamento de equipe de 50 cientistas.

1999 - 2008

Pfizer Inc.

Vínculo: Diretora, Enquadramento Funcional: Departamento de Metabolism e Farmacocinetica, Carga horária: 40, Regime: Dedicação exclusiva.

1995 - 1999

Boehringer-Ingelheim

Vínculo: Chefe de Grupo de Pesquisa, Enquadramento Funcional: Departamento de Metabolismo e Farmacocinetica, Carga horária: 40, Regime: Dedicação exclusiva.

1977 - 1979

Johnson & Johnson

Vínculo: Celetista formal, Enquadramento Funcional: técnica